Nurse Practitioner Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Michelle Surrett

Nurse Practitioner, Occupational Health Cayce, SC Nurse Practitioner

NPI 1114110665 CMS profile 10598154

3799 12Th Street Ext Ste 110, Cayce, SC 29033

Open in the dashboard

General payments

$1,511

81 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Surrett of Cayce, SC is reported in the CMS Open Payments database as having received $1,511 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Nurse Practitioner, Occupational Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $796 38
2024 General $716 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Surrett
  • Nurse Practitioner, Occupational Health median
  • Middle half of Nurse Practitioner, Occupational Health
  • National median

In program year 2025, general payments to Michelle Surrett were reported at $796. Among 58 Nurse Practitioner, Occupational Health profiles paid that year, the median was $136 and the middle half received between $49 and $382.

Show as a table
Year Michelle Surrett Nurse Practitioner, Occupational Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $113 $24–$236 $132
2022 $0 $82 $31–$285 $149
2023 $0 $111 $28–$256 $160
2024 $716 $146 $30–$580 $164
2025 $796 $136 $49–$382 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. AbbVie, Inc. $322 20 payments
  2. Corcept Therapeutics $168 5 payments
  3. AstraZeneca Pharmaceuticals LP $110 7 payments
  4. Dynavax Technologies Corporation $89 4 payments
  5. Otsuka America Pharmaceutical, Inc. $79 4 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $69 4 payments
  7. Pfizer Inc. $60 4 payments
  8. Novo Nordisk Inc $51 3 payments
  9. GlaxoSmithKline, LLC. $50 3 payments
  10. Exact Sciences Corporation $44 3 payments
  11. Other $471 24 payments

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $1,511 81 payments
Products named General payments · program years 2024–2025
  1. UBRELVY $202 14 payments
  2. Korlym $168 5 payments
  3. QULIPTA $154 11 payments
  4. XIFAXAN $138 8 payments
  5. VRAYLAR $99 5 payments
  6. Heplisav-B $89 4 payments
  7. REXULTI $79 4 payments
  8. NURTEC ODT $60 4 payments
  9. ZAVZPRET $60 4 payments
  10. BREZTRI $48 3 payments
  11. Other $969 53 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

495

Median for Nurse Practitioner: 389

Drug cost

$16,418

Median for Nurse Practitioner: $21,885

Branded share of claims

12.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 13 $12,442
Albuterol Sulfate Hfa Albuterol Sulfate Brand 23 $517
Omeprazole Generic 33 $381
Fluticasone Propionate Generic 24 $289
Duloxetine Hcl Generic 17 $219
Levetiracetam Generic 12 $217
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 26 $217
Atorvastatin Calcium Generic 26 $209
Gabapentin Generic 11 $198
Doxycycline Hyclate Generic 17 $186

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$13,042

Medicare's payments for the services billed

Medicare patients

97

Average age 71

Services billed

445

60 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 32%
Diabetes 31%
Chronic kidney disease 28%
COPD 23%
Depression 23%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $48
$48 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $40
$40 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $39
$39 — —
Heplisav-B
  • Dynavax Technologies Corporation $38
$38 — —
UBRELVY
  • AbbVie, Inc. $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Occupational Health in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record